Several studies have demonstrated that interleukin-6 (IL-6), transforming growth factor-β (TGF-β), TNF-α, CCL2, CCL17, CCL22, and other immune-regulatory cytokines have significant changes in TME and are closely related to tumor grade, invasiveness and sorafenib resistance. Here, IL6 is linked to neoplasm.